On September 11, 2020 Targazyme Inc., a late clinical-stage biopharmaceutical company developing novel fucosyltransferase enzyme technologies and products to improve clinical efficacy, safety, and cost of care outcomes for immuno-oncology and stem cell transplantation, reported that it has recruited cancer immunotherapy industry veteran James Caggiano to be the CEO, focused initially on its oncology business (Press release, Targazyme, SEP 11, 2020, View Source [SID1234565036]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
A former US Army Officer, Jim Caggiano brings nearly 30 years of immuno-oncology, pharmaceutical, and medical device experience at successful companies such as TAP Pharmaceuticals, Allergan, Abbott Laboratories, Valeant, and Dendreon. As President at Valeant, Caggiano led the successful business turnaround of Dendreon, doubled the value of Dendreon by selling it to Sanpower Group for $820M, and became its CEO. Under his leadership, Dendreon earned over $100M in EBIT in 2018 and 2019.
"We welcome Jim Caggiano to our Targazyme team and look forward to his leadership with advancing our oncology assets to making a life-changing difference for cancer patients and their families worldwide," said Lynnet Koh, Targazyme’s Founder and Executive Chairman of Targazyme. "Caggiano brings a track record of delivering major shareholder value through successful execution of sell-side deal transactions and driving major commercial revenue growth. His military leadership skills positions the company for consistently delivering on key milestones on time and on budget."
"I’m honored to join Targazyme at this exciting and pivotal time in its history," said Caggiano. "I look forward to working with the team here to capitalize on the impressive results of the past and to move these very promising, life-saving therapies forward, ultimately enhancing the lives of cancer patients."